Navigation

Humatrope (Eli Lilly)

Humatrope (Eli Lilly) - General Information

Recombinant human growth hormone (somatotropin) 191 residues, MW 22.1 kD, synthesized in E. coli

 

Pharmacology of Humatrope (Eli Lilly)

Used in the treatment of dwarfism and growth failure, growth hormone (hGH) stimulates skeletal growth in pediatric patients with growth failure due to a lack of adequate secretion of endogenous GH. Skeletal growth is accomplished at the epiphyseal plates at the ends of a growing bone. Growth and metabolism of epiphyseal plate cells are directly stimulated by GH and one of its mediators, IGF-I (insulin-like growth factor).

 

Humatrope (Eli Lilly) for patients

Patients being treated with GH and/or their parents should be informed of the potential benefits and risks associated with treatment. If home use is determined to be desirable by the physician, instructions on appropriate use should be given, including a review of the contents of the Patient Information Insert. This information is intended to aid in the safe and effective administration of the medication. It is not a disclosure of all possible adverse or intended effects.

If home use is prescribed, a puncture-resistant container for the disposal of used syringes and needles should be recommended to the patient. Patients and/or parents should be thoroughly instructed in the importance of proper disposal and cautioned against any reuse of needles and syringes.

 

Humatrope (Eli Lilly) Interactions

Excessive glucocorticoid therapy will inhibit the growth-promoting effect of human GH. Patients with ACTH deficiency should have their glucocorticoid-replacement dose carefully adjusted to avoid an inhibitory effect on growth.

The use of Nutropin in patients with chronic renal insufficiency receiving glucocorticoid therapy has not been evaluated. Concomitant glucocorticoid therapy may inhibit the growth-promoting effect of Nutropin. If glucocorticoid replacement is required, the glucocorticoid dose should be carefully adjusted.

There was no evidence in the controlled studies of Nutropin�s interaction with drugs commonly used in chronic renal insufficiency patients. Limited published data indicate that GH treatment increases cytochrome P450 (CP450) mediated antipyrine clearance in man. These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). Careful monitoring is advisable when GH is administered in combination with other drugs known to be metabolized by CP450 liver enzymes.

 

Humatrope (Eli Lilly) Contraindications

Growth hormone should not be initiated to treat patients with acute critical illness due to complications following open heart or abdominal surgery, multiple accidental trauma, or to patients having acute respiratory failure. Two placebo-controlled clinical trials in non-growth hormone-deficient adult patients (n = 522) with these conditions revealed a significant increase in mortality (41.9% vs. 19.3%) among somatropin-treated patients (doses 5.3 8 mg/day) compared to those receiving placebo.

Nutropin should not be used for growth promotion in pediatric patients with closed epiphyses.

Nutropin should not be used in patients with active neoplasia. GH therapy should be discontinued if evidence of neoplasia develops.

Nutropin, when reconstituted with Bacteriostatic Water for Injection, USP (benzyl alcohol preserved), should not be used in patients with a known sensitivity to benzyl alcohol.

Growth hormone is contraindicated in patients with Prader-Willi syndrome who are severely obese or have severe respiratory impairment. Unless patients with Prader-Willi syndrome also have a diagnosis of growth hormone deficiency, Nutropin is not indicated for the long-term treatment of pediatric patients who have growth failure due to genetically confirmed Prader-Willi syndrome.

 

Additional information about Humatrope (Eli Lilly)

Humatrope (Eli Lilly) Indication: For treatment of dwarfism, acromegaly and prevention of HIV-induced weight loss
Mechanism Of Action: hGH binds to the human growth hormone receptor (GHR). Upon binding, hGH causes dimerization of GHR, activation of the GHR-associated JAK2 tyrosine kinase, and tyrosyl phosphorylation of both JAK2 and GHR. These events recruit and/or activate a variety of signaling molecules, including MAP kinases, insulin receptor substrates, phosphatidylinositol 3' phosphate kinase, diacylglycerol, protein kinase C, intracellular calcium, and Stat transcription factors. These signaling molecules contribute to the GH-induced changes in enzymatic activity, transport function, and gene expression that ultimately culminate in changes in growth and metabolism.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Somatropin recombinant
Synonyms: GH; GH-N; Growth hormone; Growth hormone 1; Pituitary growth hormone; Somatotropin precursor; Somatropin
Drug Category: Anabolic Agents; Hormone Replacement Agents
Drug Type: Biotech; Approved; Investigational
Other Brand Names containing Somatropin recombinant: BioTropin (Biotech General); Genotropin (Pfizer); Humatrope (Eli Lilly); Norditropin (Novo Nordisk); Nutropin (Genentech Inc.); NutropinAQ (Genentech Inc.); Protropin (Genentech Inc.); Saizen (Serono SA); Serostim (Serono SA); Tev-Tropin (GATE); Serostim;
Absorption: Not Available
Toxicity (Overdose): Not Available
Protein Binding: Not Available
Biotransformation: Not Available
Half Life: Not Available
Dosage Forms of Humatrope (Eli Lilly): Injection, powder, lyophilized, for solution Subcutaneous
Chemical IUPAC Name: Human growth hormone
Chemical Formula: C990H1532N262O300S7
Somatropin recombinant on Wikipedia: https://en.wikipedia.org/wiki/Somatropin_recombinant
Organisms Affected: Humans and other mammals